<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6724046/results/search/disease/results.xml">
  <result pre=": Article Inhibitory Effects of Antiviral Drug Candidates on Canine" exact="Parvovirus" post="in F81 cells ZhouHongzhuan†SuXia†LinLuluZhangJinQiQiGuoFangfangXuFuzhouYangBing*[], *Correspondence: byang111@yeah.net; Tel.: +86-10-5150-3203 †These"/>
  <result pre="Abstract Canine parvovirus (CPV) is a common etiological agent of" exact="acute" post="enteritis, which occurs globally in domestic and wild carnivores."/>
  <result pre="of commercial vaccines. While no specific antiviral therapy for CPV" exact="infection" post="exists, the only treatment option for the infection is"/>
  <result pre="for CPV infection exists, the only treatment option for the" exact="infection" post="is supportive therapy based on symptoms. Thus, there is"/>
  <result pre="Canine parvovirus (CPV), genus Protoparvovirus, a member of the family" exact="Parvoviridae" post="(subfamily Parvovirinae), is a small, highly contagious, nonenveloped, single-stranded"/>
  <result pre="DNA virus [1]. CPV is a major causative agent of" exact="acute" post="gastroenteritis, leukopenia and myocarditis in dogs, and typical clinical"/>
  <result pre="[1]. CPV is a major causative agent of acute gastroenteritis," exact="leukopenia" post="and myocarditis in dogs, and typical clinical signs include"/>
  <result pre="is a major causative agent of acute gastroenteritis, leukopenia and" exact="myocarditis" post="in dogs, and typical clinical signs include vomiting, fever,"/>
  <result pre="months have been found to be more susceptible to CPV" exact="infection" post="[2,3]. The CPV genome is approximately 5.2 kb in"/>
  <result pre="of CPV infections. Therefore, the only treatment options for the" exact="infection" post="are supportive and symptom-based care [11,12,13]. Thus, it is"/>
  <result pre="RNA viruses, including Ebola (EBOV) [15,16], Zika (ZIKV) [14,17,18], and" exact="Hepatitis" post="B (HBV) [19] viruses. In this study, a high-throughput"/>
  <result pre="fibroblast-like monolayer cell line (F81) was originally obtained from the" exact="American" post="Type Culture Collection (ATCC). The cells were cultured in"/>
  <result pre="were infected with 10 μL CPV at a multiplicity of" exact="infection" post="(MOI) of 0.076. Normal and the CPV SD6-infected F81"/>
  <result pre="μL CPV at a multiplicity of infection (MOI) of 0.076." exact="Normal" post="and the CPV SD6-infected F81 cells containing a final"/>
  <result pre="Inc., Winooski, VT, USA). OD450 values of wells without CPV" exact="infection" post="served as a positive (cell) control indicating 100% CPE"/>
  <result pre="100% CPE inhibition, and OD450 values of wells with SD6" exact="infection" post="served as a negative (virus) control indicating 0% CPE"/>
  <result pre="100 [20,21]. All drug plates were set-up in duplicates for" exact="primary" post="screening, and drugs show greater than 20% CPE inhibition"/>
  <result pre="and drugs show greater than 20% CPE inhibition from the" exact="primary" post="screen were used for second round of screening. The"/>
  <result pre="were done in triplicate. Cell cytotoxicity and inhibition of CPV" exact="infection" post="were both examined after 40 h incubation using the"/>
  <result pre="Absolute quantification PCR was used to evaluate the anti-CPV effect." exact="Total" post="DNA was isolated from SD6 infected F81 cells using"/>
  <result pre="0.1% DMSO were used as control. After 40 h incubation," exact="total" post="DNA was extracted from whole cell lysates by QIAamp"/>
  <result pre="dilution of fluorescein isothiocyanate-conjugated Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed" exact="Secondary" post="Antibody (Invitrogen, Carlsbad, CA, USA). Finally, the cells were"/>
  <result pre="of fluorescein isothiocyanate-conjugated Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary" exact="Antibody" post="(Invitrogen, Carlsbad, CA, USA). Finally, the cells were stained"/>
  <result pre="time points following the addition of the three drugs after" exact="virus infection" post="were also evaluated by this assay. Briefly, F81 cells"/>
  <result pre="points following the addition of the three drugs after virus" exact="infection" post="were also evaluated by this assay. Briefly, F81 cells"/>
  <result pre="h incubation, cells were harvested and lysed with ProteinExt® Mammalian" exact="Total" post="Protein Extraction Kit (TransGen Biotech, China). Equal amounts of"/>
  <result pre="incubation, cells were harvested and lysed with ProteinExt® Mammalian Total" exact="Protein" post="Extraction Kit (TransGen Biotech, China). Equal amounts of cell"/>
  <result pre="Band intensities were measured using the Image J software, and" exact="viral" post="VP2 protein expression was first compared with beta Actin"/>
  <result pre="&amp;lt; 0.001. 3. Results 3.1. Screening Drug Inhibitors against CPV" exact="Infection" post="in F81 Ccells In this study, a CPE-based high-throughput"/>
  <result pre="the CPE-based assay, are shown in Figure 1A,B. In the" exact="primary" post="screen (First round), the Z’ factor was between 0.68"/>
  <result pre="these drugs, when these drugs were added 1 h post-virus" exact="infection" post="are also listed in Table S1. Seven drugs with"/>
  <result pre="Moreover, all three drugs showed a dose-dependent inhibition of CPV" exact="infection" post="(Figure 2). 3.2. Validation of Anti-CPV Drug Candidates by"/>
  <result pre="qPCR results, dose-dependent reduction in the copy numbers of CPV" exact="viral" post="DNA were observed with increasing concentrations of Nitazoxanide (Figure"/>
  <result pre="treated with the three drugs at 10 μM, the CPV" exact="viral" post="DNA copy numbers of 1mL whole cell lysates significantly"/>
  <result pre="DMSO-treated group (Figure 3). As shown in Figure 4, CPV" exact="infection" post="could be inhibited in the presence of Nitazoxanide, Closantel"/>
  <result pre="drugs. The results confirmed that these identified drugs inhibited CPV" exact="infection" post="in a dose-dependent manner, which was consistent with the"/>
  <result pre="three drugs showed anti-CPV effects when added 1 h before" exact="virus infection" post="(pre-infection). The inhibitory effects of Nitazoxanide, Closantel Sodium, and"/>
  <result pre="drugs showed anti-CPV effects when added 1 h before virus" exact="infection" post="(pre-infection). The inhibitory effects of Nitazoxanide, Closantel Sodium, and"/>
  <result pre="respectively, when the three drugs were added 1 h post-virus" exact="infection" post="(Figure 5). The drugs inhibited the early processes of"/>
  <result pre="that Nitazoxanide may partially have the ability to inhibit CPV" exact="infection" post="at the stage of viral replication. 3.4. Inhibitory Effects"/>
  <result pre="the ability to inhibit CPV infection at the stage of" exact="viral" post="replication. 3.4. Inhibitory Effects of Anti-CPV Drugs on Different"/>
  <result pre="CPV-2a, CPV-2b, and CPV-2c [4,6,8]. Currently, commercial vaccines cannot provide" exact="complete" post="protection against all CPV variants. Moreover, no effective drug"/>
  <result pre="variants. Moreover, no effective drug is available to control CPV" exact="infection" post="except for supportive and symptom-based care. Hence, it is"/>
  <result pre="inhibition of the four drugs was always maintained at a" exact="lower" post="level (Figure S1). The maximum percentage CPE inhibitions for"/>
  <result pre="51.80 ± 2.48 and 68.37 ± 7.79, which are relatively" exact="lower" post="CPE inhibition levels that would not increase with increased"/>
  <result pre="Sodium, and Closantel can reduce the copy numbers of CPV" exact="viral" post="DNA to 0.07%, 24.04%, and 20.83%, respectively, compared with"/>
  <result pre="IFA result also showed that these identified drugs inhibited CPV" exact="infection" post="in a dose-dependent reduction manner. Western blot showed that"/>
  <result pre="that the identified drugs had significant inhibitory effects against CPV" exact="infection" post="in F81 cells. In previous studies, two drugs Oseltamivir"/>
  <result pre="influenza virus. Savigny and Macintire (2010) used Oseltamivir for CPV" exact="enteritis" post="and found that the Oseltamivir-treated group gained a significant"/>
  <result pre="Nitazoxanide was used to treat cryptosporidiosis, giardiasis, and other parasitic" exact="infections" post="[27]. Recently Nitazoxanide was reported to inhibit various DNA"/>
  <result pre="was reported to inhibit various DNA and RNA viruses, including" exact="hepatitis" post="B virus (HBV) [28,29], human cytomegalovirus (HCMV) [30], influenza"/>
  <result pre="(HBV) [28,29], human cytomegalovirus (HCMV) [30], influenza A virus [31]," exact="hepatitis" post="C virus [32], norovirus [33], rotavirus [34], Japanese encephalitis"/>
  <result pre="virus [31], hepatitis C virus [32], norovirus [33], rotavirus [34]," exact="Japanese encephalitis" post="virus (JEV) [35], coronavirus [36] chikungunya virus (CHIKV) [20],"/>
  <result pre="[31], hepatitis C virus [32], norovirus [33], rotavirus [34], Japanese" exact="encephalitis" post="virus (JEV) [35], coronavirus [36] chikungunya virus (CHIKV) [20],"/>
  <result pre="[33], rotavirus [34], Japanese encephalitis virus (JEV) [35], coronavirus [36]" exact="chikungunya" post="virus (CHIKV) [20], human immunodeficiency virus (HIV) [37], and"/>
  <result pre="virus (JEV) [35], coronavirus [36] chikungunya virus (CHIKV) [20], human" exact="immunodeficiency" post="virus (HIV) [37], and ZIKV [38]. The antiviral mechanism"/>
  <result pre="PKR and eIF2α, further affecting N-linked glycosylation of the bovine" exact="viral" post="diarrhea virus (BVDV) E2 protein and trafficking from the"/>
  <result pre="and eIF2α, further affecting N-linked glycosylation of the bovine viral" exact="diarrhea" post="virus (BVDV) E2 protein and trafficking from the ER"/>
  <result pre="production of acetyl-CoA, which is a required metabolic intermediates for" exact="Vaccinia" post="virus (VACV) reproduction. In general, further studies are still"/>
  <result pre="Emerging Parvoviruses of Dogs and CatsJ. Virol.200882110961110510.1128/JVI.01003-0818768982 10.ShackeltonL.A.ParrishC.R.TruyenU.HolmesE.C.High rate of" exact="viral" post="evolution associated with the emergence of carnivore parvovirusProc. Natl."/>
  <result pre="using N-acetylcysteine in canine parvoviral enteritisJ. Vet. Pharmacol. Ther.201841687510.1111/jvp.1243428703421 12.LammC.G.RezabekG.B.Parvovirus" exact="infection" post="in domestic companion animalsVet. Clin. N. Am. Small Anim."/>
  <result pre="Veter. Med. Assoc.201224070070410.2460/javma.240.6.700 14.XuM.LeeE.M.WenZ.ChengY.HuangW.-K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.et al.Identification of small-molecule inhibitors of Zika" exact="virus infection" post="and induced neural cell death via a drug repurposing"/>
  <result pre="Med. Assoc.201224070070410.2460/javma.240.6.700 14.XuM.LeeE.M.WenZ.ChengY.HuangW.-K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.et al.Identification of small-molecule inhibitors of Zika virus" exact="infection" post="and induced neural cell death via a drug repurposing"/>
  <result pre="Mol. Med.20162291992110.1016/j.molmed.2016.09.00627692879 19.Van de KlundertM.A.ZaaijerH.L.KootstraN.A.Identification of FDA-approved drugs that target" exact="hepatitis" post="B virus transcriptionJ. Viral Hepat.20162319120110.1111/jvh.1247926456011 20.WangY.-M.LuJ.-W.LinC.-C.ChinY.-F.WuT.-Y.LinL.-I.LaiZ.-Z.KuoS.-C.HoY.-J.Antiviral activities of niclosamide"/>
  <result pre="KlundertM.A.ZaaijerH.L.KootstraN.A.Identification of FDA-approved drugs that target hepatitis B virus transcriptionJ." exact="Viral" post="Hepat.20162319120110.1111/jvh.1247926456011 20.WangY.-M.LuJ.-W.LinC.-C.ChinY.-F.WuT.-Y.LinL.-I.LaiZ.-Z.KuoS.-C.HoY.-J.Antiviral activities of niclosamide and nitazoxanide against chikungunya"/>
  <result pre="transcriptionJ. Viral Hepat.20162319120110.1111/jvh.1247926456011 20.WangY.-M.LuJ.-W.LinC.-C.ChinY.-F.WuT.-Y.LinL.-I.LaiZ.-Z.KuoS.-C.HoY.-J.Antiviral activities of niclosamide and nitazoxanide against" exact="chikungunya" post="virus entry and transmissionAntivir. Res.2016135819010.1016/j.antiviral.2016.10.00327742486 21.FangJ.SunL.PengG.XuJ.ZhouR.CaoS.ChenH.SongY.Identification of Three Antiviral"/>
  <result pre="entry and transmissionAntivir. Res.2016135819010.1016/j.antiviral.2016.10.00327742486 21.FangJ.SunL.PengG.XuJ.ZhouR.CaoS.ChenH.SongY.Identification of Three Antiviral Inhibitors against" exact="Japanese Encephalitis" post="Virus from Library of Pharmacologically Active Compounds 1280PLoS ONE20138e7842510.1371/journal.pone.007842524348901"/>
  <result pre="and transmissionAntivir. Res.2016135819010.1016/j.antiviral.2016.10.00327742486 21.FangJ.SunL.PengG.XuJ.ZhouR.CaoS.ChenH.SongY.Identification of Three Antiviral Inhibitors against Japanese" exact="Encephalitis" post="Virus from Library of Pharmacologically Active Compounds 1280PLoS ONE20138e7842510.1371/journal.pone.007842524348901"/>
  <result pre="Crit. Care20102013214210.1111/j.1476-4431.2009.00404.x20230441 26.LiekensS.NoppenS.GijsbersS.SienaertR.RoncaR.TobiaC.PrestaM.The broad-spectrum anti-DNA virus agent cidofovir inhibits lung" exact="metastasis" post="of virus-independent, FGF2-driven tumorsOncotarget201564633464810.18632/oncotarget.307925609197 27.HicksonS.E.MargineantuD.HockenberyD.M.SimonJ.A.GeballeA.P.Inhibition of vaccinia virus replication"/>
  <result pre="cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumorsOncotarget201564633464810.18632/oncotarget.307925609197 27.HicksonS.E.MargineantuD.HockenberyD.M.SimonJ.A.GeballeA.P.Inhibition of" exact="vaccinia" post="virus replication by nitazoxanideVirology201851839840510.1016/j.virol.2018.03.02329625403 28.KorbaB.E.MonteroA.B.FarrarK.GayeK.MukerjeeS.AyersM.S.RossignolJ.-F.Nitazoxanide, tizoxanide and other thiazolides"/>
  <result pre="nitazoxanideVirology201851839840510.1016/j.virol.2018.03.02329625403 28.KorbaB.E.MonteroA.B.FarrarK.GayeK.MukerjeeS.AyersM.S.RossignolJ.-F.Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of" exact="hepatitis" post="B virus and hepatitis C virus replicationAntivir. Res.200877566310.1016/j.antiviral.2007.08.00517888524 29.StachulskiA.V.PidathalaC.RowE.C.SharmaR.BerryN.G.IqbalM.BentleyJ.AllmanS.A.EdwardsG.HelmA.et"/>
  <result pre="other thiazolides are potent inhibitors of hepatitis B virus and" exact="hepatitis" post="C virus replicationAntivir. Res.200877566310.1016/j.antiviral.2007.08.00517888524 29.StachulskiA.V.PidathalaC.RowE.C.SharmaR.BerryN.G.IqbalM.BentleyJ.AllmanS.A.EdwardsG.HelmA.et al.Thiazolides as Novel Antiviral"/>
  <result pre="Res.200877566310.1016/j.antiviral.2007.08.00517888524 29.StachulskiA.V.PidathalaC.RowE.C.SharmaR.BerryN.G.IqbalM.BentleyJ.AllmanS.A.EdwardsG.HelmA.et al.Thiazolides as Novel Antiviral Agents. 1. Inhibition of" exact="Hepatitis" post="B Virus ReplicationJ. Med. Chem.2011544119413210.1021/jm200153p21553812 30.MercorelliB.LuganiniA.NannettiG.TabarriniO.PalúG.GribaudoG.LoregianA.Drug Repurposing Approach Identifies"/>
  <result pre="Med. Chem.2011544119413210.1021/jm200153p21553812 30.MercorelliB.LuganiniA.NannettiG.TabarriniO.PalúG.GribaudoG.LoregianA.Drug Repurposing Approach Identifies Inhibitors of the Prototypic" exact="Viral" post="Transcription Factor IE2 that Block Human Cytomegalovirus ReplicationCell Chem."/>
  <result pre="Boil.20162334035110.1016/j.chembiol.2015.12.012 31.RossignolJ.F.La FraziaS.ChiappaL.CiucciA.SantoroM.G.Thiazolides, a New Class of Anti-influenza Molecules Targeting" exact="Viral" post="Hemagglutinin at the Post-translational LevelJ. Boil. Chem.2009284297982980810.1074/jbc.M109.029470 32.KeeffeE.B.RossignolJ.-F.KeeffeJ.-F.E.B.RossignolO.Treatment of"/>
  <result pre="Viral Hemagglutinin at the Post-translational LevelJ. Boil. Chem.2009284297982980810.1074/jbc.M109.029470 32.KeeffeE.B.RossignolJ.-F.KeeffeJ.-F.E.B.RossignolO.Treatment of" exact="chronic" post="viral hepatitis with nitazoxanide and second generation thiazolidesWorld J."/>
  <result pre="Hemagglutinin at the Post-translational LevelJ. Boil. Chem.2009284297982980810.1074/jbc.M109.029470 32.KeeffeE.B.RossignolJ.-F.KeeffeJ.-F.E.B.RossignolO.Treatment of chronic" exact="viral hepatitis" post="with nitazoxanide and second generation thiazolidesWorld J. Gastroenterol.2009151805180810.3748/wjg.15.180519370775 33.SiddiqD.M.KooH.L.AdachiJ.A.ViolaG.M.Norovirus"/>
  <result pre="at the Post-translational LevelJ. Boil. Chem.2009284297982980810.1074/jbc.M109.029470 32.KeeffeE.B.RossignolJ.-F.KeeffeJ.-F.E.B.RossignolO.Treatment of chronic viral" exact="hepatitis" post="with nitazoxanide and second generation thiazolidesWorld J. Gastroenterol.2009151805180810.3748/wjg.15.180519370775 33.SiddiqD.M.KooH.L.AdachiJ.A.ViolaG.M.Norovirus"/>
  <result pre="New Class of Antiviral Agents Effective against Rotavirus Infection, Target" exact="Viral" post="Morphogenesis, Inhibiting Viroplasm FormationJ. Virol.201387110961110610.1128/JVI.01213-1323926336 35.ShiZ.WeiJ.DengX.LiS.QiuY.ShaoD.LiB.ZhangK.XueF.WangX.et al.Nitazoxanide inhibits the"/>
  <result pre="Inhibiting Viroplasm FormationJ. Virol.201387110961110610.1128/JVI.01213-1323926336 35.ShiZ.WeiJ.DengX.LiS.QiuY.ShaoD.LiB.ZhangK.XueF.WangX.et al.Nitazoxanide inhibits the replication of" exact="Japanese encephalitis" post="virus in cultured cells and in a mouse modelVirol."/>
  <result pre="Viroplasm FormationJ. Virol.201387110961110610.1128/JVI.01213-1323926336 35.ShiZ.WeiJ.DengX.LiS.QiuY.ShaoD.LiB.ZhangK.XueF.WangX.et al.Nitazoxanide inhibits the replication of Japanese" exact="encephalitis" post="virus in cultured cells and in a mouse modelVirol."/>
  <result pre="Choice for Control of ZikaOpen Forum Infect. Dis.20174ofx00910.1093/ofid/ofx00928480282 39.PerelyginaL.HautalaT.SeppänenM.AdebayoA.SullivanK.E.IcenogleJ.Inhibition of" exact="rubella" post="virus replication by the broad-spectrum drug nitazoxanide in cell"/>
  <result pre="nitazoxanide in cell culture and in a patient with a" exact="primary" post="immune deficiencyAntivir. Res.2017147586610.1016/j.antiviral.2017.09.01928974385 40.LiZ.BrecherM.DengY.-Q.ZhangJ.SakamuruS.LiuB.HuangR.A KoetznerC.A AllenC.A JonesS.et al.Existing drugs"/>
  <result pre="cation chloride transportersJ. Am. Soc. Nephrol.2015571525153610.1681/ASN.201406056025377078 43.ZhuX.-Y.XiaB.LiuH.-C.XuY.-Q.HuangC.-J.GaoJ.-M.DongQ.-X.LiC.-Q.Closantel Suppresses Angiogenesis and" exact="Cancer" post="Growth in Zebrafish ModelsASSAY Drug Dev. Technol.20161428229010.1089/adt.2015.67927045536 44.LiY.GuoB.XuZ.LiB.CaiT.ZhangX.YuY.WangH.ShiJ.ZhuW.Repositioning organohalogen"/>
  <result pre="Drug Nitazoxanide as a Candidate for Treatment of Colorectal CancerMol." exact="Cancer" post="Ther.2015141504151610.1158/1535-7163.MCT-14-079225911689 Figure 1 Screening of the FDA-approved compound library"/>
  <result pre="CPE inhibition. Twenty-one drugs showing &amp;gt;20% CPE inhibition from the" exact="primary" post="screen were used for a second round of screening,"/>
  <result pre="effects of the identified drugs were analyzed by quantification of" exact="viral" post="DNAs. F81 cells seeded in 6-well plates were pretreated"/>
  <result pre="(A), Closantel Sodium (B), or Closantel (C) before CPV infection." exact="Total" post="DNA was extracted at 40 hpi from whole cell"/>
  <result pre="and Closantel, respectively, at different time points, designated prior to" exact="infection" post="(−1 h), during infection (0 h), postinfection (0.5 h,"/>
  <result pre="different time points, designated prior to infection (−1 h), during" exact="infection" post="(0 h), postinfection (0.5 h, 1 h, 2 h,"/>
  <result pre="Caspase 3/7 activity of F81 cells with or without CPV" exact="infection" post="were analyzed at 4 hpi, 8 hpi, 12 hpi,"/>
 </snippets>
</snippetsTree>
